Medtronic (NYSE:MDT) Announces Earnings Results, Beats Estimates By $0.06 EPS

Medtronic (NYSE:MDT) announced its earnings results on Tuesday. The medical technology company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06, FiscalAI reports. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The company had revenue of $9.76 billion for the quarter, compared to analysts’ expectations of $9.55 billion.

Medtronic Stock Performance

MDT opened at $90.82 on Tuesday. The stock has a market capitalization of $116.25 billion, a price-to-earnings ratio of 24.35, a PEG ratio of 2.45 and a beta of 0.55. The company has a fifty day moving average of $85.81 and a 200 day moving average of $85.48. Medtronic has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.62 and a current ratio of 2.13.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Investors of record on Friday, September 25th will be given a dividend of $0.72 per share. The ex-dividend date is Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.2%. Medtronic’s dividend payout ratio is currently 77.21%.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Jefferies Financial Group reaffirmed a “hold” rating and issued a $88.00 price objective on shares of Medtronic in a research note on Thursday, June 4th. Mizuho decreased their target price on shares of Medtronic from $120.00 to $100.00 and set an “outperform” rating on the stock in a research note on Wednesday, June 3rd. Wells Fargo & Company lowered their price target on shares of Medtronic from $114.00 to $102.00 and set an “overweight” rating on the stock in a report on Thursday, June 4th. Piper Sandler reiterated a “neutral” rating on shares of Medtronic in a research report on Monday, August 10th. Finally, Needham & Company LLC raised their price objective on shares of Medtronic from $101.00 to $114.00 and gave the company a “buy” rating in a research report on Thursday, August 27th. Eighteen research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, Medtronic currently has a consensus rating of “Moderate Buy” and an average price target of $99.79.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic announced a strategic investment in Pi-Cardia Ltd. to accelerate innovation for complex transcatheter aortic valve replacement (TAVR) procedures. The deal could strengthen Medtronic’s structural-heart portfolio and support longer-term growth, although financial terms were not disclosed. Medtronic Announces Strategic Investment in Pi-Cardia to Accelerate Innovation for Complex TAVR
• Positive Sentiment: Wall Street’s average brokerage recommendation remains equivalent to a Buy, indicating continued confidence in Medtronic’s defensive healthcare profile, cash generation and dividend. However, the article cautions that bullish analyst ratings may be overly optimistic and should not be used alone to make an investment decision. Brokers Suggest Investing in Medtronic
• Neutral Sentiment: Medtronic’s fiscal first-quarter 2027 earnings were scheduled for release before the market opened on Sept. 1. Analysts cited in the previews expected approximately $1.39 in adjusted EPS and $9.54 billion in revenue, making the report the main near-term catalyst for the stock. Medtronic Q1 Earnings on Deck: What to Expect
• Neutral Sentiment: Medtronic is highlighted among stocks to watch as investors await its earnings announcement, but the article provides no company-specific change to its outlook. Medtronic, Dell and 3 Stocks to Watch
• Negative Sentiment: Pre-earnings commentary warned that Medtronic shares could fall following the results, reflecting the risk that earnings, revenue or guidance may not meet elevated expectations. Broader weakness in U.S. equity futures, linked partly to renewed geopolitical tensions and interest-rate concerns, also creates a less supportive market environment. Will Medtronic Stock Rise or Fall After Earnings?

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the business’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the sale, the executive vice president owned 37,227 shares in the company, valued at $2,994,539.88. The trade was a 10.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Quadrant Capital Group LLC lifted its position in shares of Medtronic by 0.3% in the fourth quarter. Quadrant Capital Group LLC now owns 32,477 shares of the medical technology company’s stock worth $3,120,000 after buying an additional 101 shares in the last quarter. Rossby Financial LCC grew its holdings in Medtronic by 5.1% during the 4th quarter. Rossby Financial LCC now owns 2,193 shares of the medical technology company’s stock valued at $211,000 after buying an additional 107 shares in the last quarter. Wealthspire Retirement LLC grew its holdings in Medtronic by 5.0% during the 4th quarter. Wealthspire Retirement LLC now owns 2,410 shares of the medical technology company’s stock valued at $232,000 after buying an additional 114 shares in the last quarter. Mitchell Mcleod Pugh & Williams Inc. increased its stake in Medtronic by 2.0% in the 4th quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 6,043 shares of the medical technology company’s stock worth $622,000 after acquiring an additional 117 shares during the last quarter. Finally, Florida Financial Advisors LLC increased its stake in Medtronic by 4.8% in the 2nd quarter. Florida Financial Advisors LLC now owns 2,683 shares of the medical technology company’s stock worth $234,000 after acquiring an additional 122 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).